Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.
Current Value
$1.551 Year Return
Current Value
$1.551 Year Return
Market Cap
$43.27M
P/E Ratio
-0.48
1Y Stock Return
-28.64%
1Y Revenue Growth
-22.81%
Dividend Yield
0.00%
Price to Book
2.0
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Yahoo
Fortress Biotech ( NASDAQ:FBIO ) Third Quarter 2024 Results Key Financial Results Revenue: US$14.6m (down 7.1% from 3Q...
Yahoo
BAY HARBOR ISLAND, Fla. AP) — Fortress Biotech Inc. FBIO) on Thursday reported a loss of $12.9 million in its third quarter.
Yahoo
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally advanced cutaneous squamous cell carcinoma MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings
Yahoo
- Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the third quarter ended September 30, 2024. “We have gen
Yahoo
Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2024, and recent corporate updates. “With the Prescription Drug User Fee Act (“PDUFA”) goal date set for next month, we await the decision by t
Yahoo
U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025 Total revenues for the third quarter ended September 30, 2024 were $14.6 million SCOTTSDALE, Ariz., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on the
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BKD | 37.79% | $1.06B | +1.91% | 0.00% |
PGEN | 36.75% | $259.78M | -20.80% | 0.00% |
PRTA | 36.52% | $777.00M | -55.88% | 0.00% |
ARWR | 35.02% | $2.27B | -36.88% | 0.00% |
ATXS | 34.76% | $527.10M | +110.36% | 0.00% |
ALEC | 34.15% | $368.23M | -22.31% | 0.00% |
EYPT | 33.60% | $446.88M | +39.17% | 0.00% |
DMRC | 33.44% | $672.94M | -3.39% | 0.00% |
GBIO | 33.35% | $88.17M | +14.78% | 0.00% |
AQB | 33.15% | $3.75M | -53.98% | 0.00% |
LPTX | 33.08% | $98.86M | -9.79% | 0.00% |
GAP | 32.99% | $8.29B | +17.23% | 2.44% |
AVXL | 32.97% | $764.86M | +34.63% | 0.00% |
RGNX | 32.73% | $454.82M | -52.01% | 0.00% |
GDOT | 32.64% | $551.31M | +22.61% | 0.00% |
CYRX | 32.15% | $322.29M | -53.49% | 0.00% |
NXDT | 31.93% | $218.01M | -37.12% | 11.55% |
SEER | 31.78% | $140.34M | +45.12% | 0.00% |
YMAB | 31.18% | $452.37M | +85.32% | 0.00% |
ALDX | 31.15% | $286.43M | +90.12% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TNK | -0.02% | $1.44B | -17.00% | 2.40% |
CBOE | -0.02% | $22.09B | +17.17% | 1.08% |
VIV | -0.08% | $14.22B | -13.28% | 0.00% |
LNW | 0.08% | $8.34B | +8.03% | 0.00% |
FAT | -0.09% | $91.75M | -8.47% | 10.57% |
AJG | 0.14% | $66.36B | +20.50% | 0.77% |
SEA | 0.17% | $1.37B | +32.72% | 0.00% |
MO | 0.17% | $94.96B | +36.03% | 7.02% |
BYRN | -0.18% | $456.55M | +279.63% | 0.00% |
GALT | -0.22% | $170.71M | +33.99% | 0.00% |
FENG | -0.23% | $13.53M | +94.49% | 0.00% |
MNST | 0.24% | $52.50B | -2.25% | 0.00% |
MKL | -0.25% | $22.10B | +20.21% | 0.00% |
SNY | 0.25% | $120.29B | +3.27% | 4.24% |
AIFU | -0.27% | $70.89M | -81.83% | 0.00% |
CTRE | 0.28% | $5.76B | +33.94% | 3.72% |
E | -0.29% | $45.95B | -10.47% | 7.33% |
PSQH | 0.30% | $76.13M | -59.59% | 0.00% |
CSCO | -0.31% | $229.44B | +19.72% | 2.76% |
WEC | 0.34% | $31.94B | +23.91% | 3.31% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -32.82% | $379.51M | 1.43% |
VIXY | -13.70% | $195.31M | 0.85% |
BSCO | -13.37% | $2.31B | 0.1% |
USDU | -12.41% | $201.83M | 0.5% |
TAIL | -11.24% | $68.06M | 0.59% |
AGZD | -9.22% | $142.85M | 0.23% |
UUP | -8.64% | $359.07M | 0.77% |
EQLS | -7.88% | $8.88M | 1% |
KMLM | -7.79% | $348.59M | 0.9% |
JBBB | -7.53% | $1.27B | 0.49% |
CLOI | -7.38% | $720.91M | 0.4% |
MINT | -7.15% | $11.62B | 0.35% |
DFSD | -6.79% | $3.62B | 0.16% |
BUXX | -6.42% | $166.76M | 0.25% |
BOXX | -6.36% | $4.43B | 0.1949% |
UNG | -6.15% | $928.64M | 1.06% |
TBIL | -5.56% | $4.39B | 0.15% |
CTA | -5.42% | $359.48M | 0.78% |
JUCY | -5.33% | $325.31M | 0.6% |
XHLF | -4.39% | $883.02M | 0.03% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
VZIO | -15.14% | $2.29B | +66.81% | 0.00% |
CHD | -14.37% | $27.50B | +19.29% | 1.01% |
CL | -13.94% | $77.00B | +21.96% | 2.09% |
HOLX | -13.49% | $18.28B | +9.06% | 0.00% |
SPB | -12.60% | $2.53B | +37.47% | 1.85% |
BSM | -12.13% | $3.23B | -12.29% | 10.44% |
ACGL | -11.80% | $37.09B | +20.63% | 0.00% |
MNOV | -11.31% | $98.09M | +5.26% | 0.00% |
RNR | -11.25% | $13.75B | +22.34% | 0.58% |
PG | -11.11% | $406.83B | +14.39% | 2.27% |
PULM | -10.98% | $22.32M | +230.27% | 0.00% |
TCTM | -10.72% | $7.57M | -41.30% | 0.00% |
PGR | -10.71% | $154.33B | +62.01% | 0.44% |
MCK | -10.56% | $79.75B | +37.34% | 0.41% |
CYCN | -10.55% | $3.85M | -33.95% | 0.00% |
ADBE | -10.31% | $222.05B | -18.60% | 0.00% |
NOC | -9.99% | $72.32B | +5.29% | 1.58% |
LMT | -9.71% | $128.48B | +20.34% | 2.32% |
EG | -9.35% | $16.55B | -5.60% | 1.93% |
APRE | -8.69% | $15.89M | -20.58% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBDP | 0.10% | $2.05B | 0.1% |
SHY | -0.12% | $22.50B | 0.15% |
HIGH | 0.20% | $301.36M | 0.51% |
IBDQ | -0.20% | $2.90B | 0.1% |
IBTH | 0.23% | $1.08B | 0.07% |
DBMF | -0.25% | $1.02B | 0.85% |
XLP | -0.31% | $16.04B | 0.09% |
SPTS | -0.34% | $5.70B | 0.03% |
UTWO | -0.50% | $442.66M | 0.15% |
FMF | 0.68% | $243.44M | 0.95% |
XBIL | 0.87% | $637.84M | 0.15% |
IBTG | 0.92% | $1.49B | 0.07% |
VGSH | -0.96% | $19.13B | 0.04% |
DBE | 1.04% | $50.92M | 0.77% |
IYK | -1.13% | $1.31B | 0.4% |
SCHO | -1.19% | $11.11B | 0.03% |
XONE | -1.19% | $550.61M | 0.03% |
GCOR | 1.21% | $393.62M | 0.14% |
DUSB | -1.23% | $812.64M | 0.15% |
KRBN | 1.42% | $243.28M | 0.85% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 42.46% | $6.75B | 0.35% |
IWC | 42.02% | $943.89M | 0.6% |
GNOM | 39.72% | $71.22M | 0.5% |
PBE | 39.35% | $253.13M | 0.58% |
PTH | 39.25% | $141.72M | 0.6% |
VTWO | 38.18% | $12.48B | 0.1% |
IWM | 38.13% | $75.93B | 0.19% |
ARKG | 37.87% | $1.14B | 0.75% |
IWN | 37.77% | $13.20B | 0.24% |
PBW | 37.68% | $297.98M | 0.65% |
IWO | 37.54% | $12.75B | 0.24% |
KOMP | 37.47% | $2.11B | 0.2% |
NUSC | 37.22% | $1.28B | 0.31% |
PRFZ | 37.12% | $2.64B | 0.39% |
ISCG | 36.99% | $648.27M | 0.06% |
ESML | 36.76% | $1.91B | 0.17% |
SLYV | 36.72% | $4.12B | 0.15% |
GSSC | 36.72% | $533.32M | 0.2% |
VIOV | 36.46% | $1.44B | 0.15% |
IBB | 36.45% | $6.64B | 0.45% |